Bestat Announces Strategic Acquisition of Trifecta MedTek
On February 2, 2026, Bestat Pharmaservices Corp. (“Bestat”) announced the completion of its strategic acquisition of Trifecta MedTek Co., Ltd. (formerly Trineo Biotechnology Co., Ltd.). This transaction represents a significant milestone in the evolution of Taiwan’s biopharmaceutical services industry and marks a pivotal step in Bestat’s long-term growth strategy.
By integrating Trifecta MedTek’s strong preclinical capabilities with Bestat’s established clinical trial expertise, the acquisition creates Taiwan’s first fully integrated, end-to-end service platform spanning from preclinical research through clinical development. This comprehensive model positions Bestat as the only CRO in Taiwan capable of delivering seamless, one-stop solutions across the entire biopharmaceutical R&D value chain, opening a new chapter for the advancement of Taiwan’s biotech ecosystem.
Trifecta MedTek: A Robust Preclinical Platform Built on Rigorous Standards
Trifecta MedTek, formerly a subsidiary of the Double Crane Group, has long been recognized for its stringent quality standards, sound operational governance, and well-established infrastructure. The company operates large-scale, fully equipped laboratories dedicated to critical preclinical testing services, supporting complex pharmacology and toxicology studies essential to early-stage drug development.
Its high-standard facilities and disciplined operational systems ensure the reliability, integrity, and regulatory readiness of safety and efficacy data prior to first-in-human trials. Through this acquisition, Bestat strategically strengthens its upstream capabilities, filling a key gap in the early phases of drug development and significantly enhancing the depth and completeness of its service portfolio.
Bestat: More Than a Decade of Leadership in Clinical Trial Execution
Founded in Taipei in 2013, Bestat has grown into one of Taiwan’s leading clinical research organizations, recognized for its execution excellence, regulatory rigor, and professional integrity. Under the leadership of Chief Executive Officer Samuel Su, Bestat has built a strong track record across a broad range of therapeutic areas.
By the end of 2024, Bestat had accumulated clinical trial experience across more than 20 therapeutic indications, including over 80 oncology studies, with cumulative involvement of more than 1,500 study subjects. The company has also played a pioneering role in Taiwan’s integration into global clinical research. In 2014, Bestat conducted Taiwan’s first Phase II clinical trial for a botanical drug and the nation’s first Phase III breast cancer trial.
In 2020, Bestat expanded its international footprint by executing a Phase II COVID-19 vaccine trial in the United States, followed by its first U.S.-based Phase III clinical trial in 2024. Throughout its history, Bestat has consistently demonstrated strong regulatory compliance, successfully passing multiple rigorous GCP inspections and maintaining alignment with international quality standards.
A Strategic Milestone in 2026: Building a Fully Integrated CRO Ecosystem
With the completion of the acquisition on February 2, 2026, Bestat reaches a new milestone in Taiwan’s biopharmaceutical services landscape. To ensure effective integration and maximize operational synergies, Bestat appointed Dr. Sean Chen as Chairman of Trifecta MedTek and Dr. Leo Huang as Chief Executive Officer.
This leadership alignment enables the seamless integration of preclinical and clinical operations, effectively bridging the long-standing gap between non-clinical research and human clinical trials. As a result, Bestat becomes the only CRO in Taiwan capable of delivering a fully integrated, end-to-end development solution under a unified management and quality framework.
This model allows biopharmaceutical companies to collaborate with a single strategic partner rather than coordinating multiple vendors, significantly reducing communication complexity, shortening development timelines, and accelerating the path from discovery to market.
Advancing Sustainable Development and Industry Competitiveness
Beyond business expansion, this acquisition closely aligns with the United Nations Sustainable Development Goals (SDGs). By enhancing the efficiency and integration of drug and medical device development, Bestat strengthens its ability to deliver innovative therapies to patients, contributing directly to SDG 3: Good Health and Well-Being.
At the same time, the expansion of operational scale and service integration supports industry upgrading and the creation of high-quality employment opportunities, reflecting SDG 8: Decent Work and Economic Growth.
This acquisition significantly enhances Bestat’s technical capabilities, service depth, and market competitiveness. Looking ahead, Bestat will continue to leverage its integrated platform to drive sustainable growth, strengthen Taiwan’s biopharmaceutical industry, and contribute meaningfully to global health and societal well-being.
On February 2, 2026, Bestat Pharmaservices Corp. (“Bestat”) announced the completion of its strategic acquisition of Trifecta MedTek Co., Ltd. (formerly Trineo Biotechnology Co., Ltd.). This transaction represents a significant milestone in the evolution of Taiwan’s biopharmaceutical services industry and marks a pivotal step in Bestat’s long-term growth strategy.
By integrating Trifecta MedTek’s strong preclinical capabilities with Bestat’s established clinical trial expertise, the acquisition creates Taiwan’s first fully integrated, end-to-end service platform spanning from preclinical research through clinical development. This comprehensive model positions Bestat as the only CRO in Taiwan capable of delivering seamless, one-stop solutions across the entire biopharmaceutical R&D value chain, opening a new chapter for the advancement of Taiwan’s biotech ecosystem.
Trifecta MedTek: A Robust Preclinical Platform Built on Rigorous Standards
Trifecta MedTek, formerly a subsidiary of the Double Crane Group, has long been recognized for its stringent quality standards, sound operational governance, and well-established infrastructure. The company operates large-scale, fully equipped laboratories dedicated to critical preclinical testing services, supporting complex pharmacology and toxicology studies essential to early-stage drug development.
Its high-standard facilities and disciplined operational systems ensure the reliability, integrity, and regulatory readiness of safety and efficacy data prior to first-in-human trials. Through this acquisition, Bestat strategically strengthens its upstream capabilities, filling a key gap in the early phases of drug development and significantly enhancing the depth and completeness of its service portfolio.
Bestat: More Than a Decade of Leadership in Clinical Trial Execution
Founded in Taipei in 2013, Bestat has grown into one of Taiwan’s leading clinical research organizations, recognized for its execution excellence, regulatory rigor, and professional integrity. Under the leadership of Chief Executive Officer Samuel Su, Bestat has built a strong track record across a broad range of therapeutic areas.
By the end of 2024, Bestat had accumulated clinical trial experience across more than 20 therapeutic indications, including over 80 oncology studies, with cumulative involvement of more than 1,500 study subjects. The company has also played a pioneering role in Taiwan’s integration into global clinical research. In 2014, Bestat conducted Taiwan’s first Phase II clinical trial for a botanical drug and the nation’s first Phase III breast cancer trial.
In 2020, Bestat expanded its international footprint by executing a Phase II COVID-19 vaccine trial in the United States, followed by its first U.S.-based Phase III clinical trial in 2024. Throughout its history, Bestat has consistently demonstrated strong regulatory compliance, successfully passing multiple rigorous GCP inspections and maintaining alignment with international quality standards.
A Strategic Milestone in 2026: Building a Fully Integrated CRO Ecosystem
With the completion of the acquisition on February 2, 2026, Bestat reaches a new milestone in Taiwan’s biopharmaceutical services landscape. To ensure effective integration and maximize operational synergies, Bestat appointed Dr. Sean Chen as Chairman of Trifecta MedTek and Dr. Leo Huang as Chief Executive Officer.
This leadership alignment enables the seamless integration of preclinical and clinical operations, effectively bridging the long-standing gap between non-clinical research and human clinical trials. As a result, Bestat becomes the only CRO in Taiwan capable of delivering a fully integrated, end-to-end development solution under a unified management and quality framework.
This model allows biopharmaceutical companies to collaborate with a single strategic partner rather than coordinating multiple vendors, significantly reducing communication complexity, shortening development timelines, and accelerating the path from discovery to market.
Advancing Sustainable Development and Industry Competitiveness
Beyond business expansion, this acquisition closely aligns with the United Nations Sustainable Development Goals (SDGs). By enhancing the efficiency and integration of drug and medical device development, Bestat strengthens its ability to deliver innovative therapies to patients, contributing directly to SDG 3: Good Health and Well-Being.
At the same time, the expansion of operational scale and service integration supports industry upgrading and the creation of high-quality employment opportunities, reflecting SDG 8: Decent Work and Economic Growth.
This acquisition significantly enhances Bestat’s technical capabilities, service depth, and market competitiveness. Looking ahead, Bestat will continue to leverage its integrated platform to drive sustainable growth, strengthen Taiwan’s biopharmaceutical industry, and contribute meaningfully to global health and societal well-being.